Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting. Roche has ...

This is not a new idea; a Python approach was first described in this paper. However, to my knowledge, CrossHair is the most complete implementation: it can use symbolic reasoning for the built-in ...